Bacteroides salanitronis is a species within the Bacteroidetes phylum, which is an essential part of the human gut microbiota.
This gram-negative, non-motile, rod-shaped bacterium thrives in anaerobic conditions and ferments various carbohydrates, producing acetic and succinic acids, with minor isovaleric acid.
It degrades and assimilates glycosaminoglycans (GAGs) and mucin, producing essential amino acids, GABA, and short-chain fatty acids.
These metabolites support gut health, immune function, and potentially mental health, highlighting its role in maintaining a balanced and beneficial gut microbiome.
Bacteroides spp., members of the Bacteroidetes phylum, are significant components of the human gut microbiota, crucial for maintaining gut homeostasis.
This phylum, constituting about 30% of the human gut microbiota, includes several genera such as Bacteroides, Prevotella, and Porphyromonas.
The proportion of Bacteroidetes varies based on population, geography, age, and diet.
Bacteroides spp. are gram-negative, non-spore forming, anaerobic, rod-shaped bacteria. Approximately 24 species have been identified, with Bacteroides fragilis and Bacteroides thetaiotaomicron being the most studied.
These bacteria thrive in anaerobic conditions, utilizing complex polysaccharides for energy through fermentation.
They possess unique genetic and metabolic features that enable efficient degradation of dietary fibers and carbohydrates, producing short-chain fatty acids (SCFAs) and other metabolites that impact host physiology.
The Bacteroides genus uses a Type VI secretion system to maintain competitive advantage in the gut. [28.]
The T4SS in Bacteroides helps maintain competition and balance in the human gut by releasing toxins that target other bacteria, enabling these bacteria to outcompete others and stabilize the gut ecosystem, often through the transfer of these systems via mobile genetic elements among neighboring strains. [28.]
Bacteroides spp. are key members of the human gut microbiome, significantly contributing to the microbial community in the colon.
Their presence and abundance are influenced by diet, host genetics, and environmental exposures.
Bacteroides spp. interact with other commensal bacteria and host cells, participating in complex microbial networks that regulate immune responses, nutrient metabolism, and intestinal barrier function.
Bacteroidetes, primarily found in the distal gut, possess a similar function of harvesting energy from diet through the fermentation of indigestible polysaccharides, producing short-chain fatty acids (SCFAs). [27.]
In adults, Bacteroides and other Bacteroidetes produce SCFAs such as acetate, propionate, and butyrate from the fermentation of undigested dietary polysaccharides. SCFAs play crucial roles in gut health, glucose homeostasis, and lipid metabolism.
Bacteroides and Prevotella are major contributors to SCFA production, especially propionate. These bacteria adapt flexibly to the gut's nutritional environment, using a wide range of dietary polysaccharides and proteins.
Despite their diversity, Bacteroidetes share a high capacity for polysaccharide utilization, aided by numerous carbohydrate-active enzymes (CAZYmes). Their metabolic flexibility allows them to switch between different substrates based on availability and competition within the gut ecosystem. [8.]
Diet and Bacteroidetes:
Diet significantly influences Bacteroidetes levels.
Diets rich in animal products increase Bacteroides levels, whereas plant-based diets promote a more diverse microbial community. [8., 29.]
Overnutrition decreases Bacteroidetes, affecting energy harvest efficiency. Conversely, undernutrition and fasting can either increase or deplete Bacteroidetes levels, depending on the conditions. [8.]
Bacteroidetes and Metabolic Diseases:
Studies show varied associations between Bacteroidetes and type 2 diabetes. The relative abundance of Bacteroidetes can affect glucose metabolism differently in individuals, influenced by diet and other factors.
Gnotobiotic animal studies show specific Bacteroidetes species can have different effects on host metabolism. Daily dosing with Bacteroides cultures improved glucose tolerance and insulin sensitivity in mice, suggesting microbial metabolites as potential metabolic effectors.
However, high Bacteroides have also been associated with impaired glucose tolerance. Bacteroides species' levels correlate with glucose responses post-meal, emphasizing the importance of dietary context. [8.]
In one study, continuous blood glucose monitoring in 800 participants showed that the relative abundance of Bacteroidetes in stool was associated with a poor postprandial glucose response. [8.]
However, within the phylum, many Bacteroides species correlated positively with a healthy postprandial glucose response when participants consumed diets optimized to their individual microbiota, dietary habits, and other factors. [8.]
Overall, the effects of Bacteroidetes on glucose metabolism can vary significantly depending on dietary context and on the relative levels of Bacteroides subspecies. [8.]
However, overall a healthy amount of Bacteroides seems to be beneficial for human metabolic health. [8., 11.]
Modulating Bacteroides metabolism through dietary interventions holds potential for restoring gut microbiota balance and promoting metabolic health.
Imbalances in the composition of the gut microbiota, including alterations in Bacteroides spp. abundance, have been associated with numerous disease states.
Bacteroidetes have been associated with metabolic disease, although the association between Bacteroidetes and metabolic diseases like obesity and type 2 diabetes is complex and context-dependent. [8.]
Bacteroides has shown potential in preventing and treating non-alcoholic fatty liver disease (NAFLD) by modulating gut health. [27.]
By reducing liver inflammation, mitigating hepatic steatosis, and enhancing intestinal barrier function, they contribute to metabolic regulation, improve insulin resistance, and balance cytokines.
While the mechanisms are not fully understood, Bacteroides’ ability to influence lipid metabolism and gut barrier integrity positions them as promising candidates for NAFLD therapy, although more clinical research is needed to confirm their efficacy.
The Bacteroides salanitronis strain is a Gram-negative, non-motile, rod-shaped bacterium that is strictly anaerobic.
It can ferment glucose, mannose, sucrose, maltose, arabinose, cellobiose, lactose, xylose, and raffinose. The primary fermentation products are acetic acid and succinic acid, with small amounts of isovaleric acid. [6.]
Menaquinones MK-11 and MK-12 are its principal respiratory quinones. [10.]
Bacteroides salanitronis also produces GABA, or gamma-aminobutyric acid, a calming neurotransmitter beneficial for human health. [18.]
The genus Bacteroides has undergone significant taxonomic revisions over the past few decades, and several new species have been added.
Bacteroides salanitronis is noted as one of these newly identified species, having recently been added to the genus Bacteroides along with others such as Bacteroides goldsteinii, Bacteroides nordii, and Bacteroides plebeius. [21.]
These species were isolated from various sources, such as human feces and blood cultures, highlighting the diversity and adaptability of the Bacteroides genus in different environments within the human body. [21.]
Bacteroides salanitronis is prevalent in omnivorous diets compared to other dietary patterns. [25.]
This species, like others in the genus, plays a significant role in metabolizing complex carbohydrates and maintaining gut health, but can also become pathogenic under certain conditions. [25.]
Bacteroides salanitronis plays a beneficial role in human health by degrading and assimilating host-derived mucosubstances, such as glycosaminoglycans (GAGs) and mucin, from the mucus lining of the gut.
This bacterium can thrive even during undernutrition or fasting conditions, producing essential amino acids, gamma-aminobutyric acid (GABA), and short-chain fatty acids.
These metabolites support gut health, improve the immune system, provide energy, and potentially benefit mental health.
Thus, Bacteroides salanitronis contributes to a mutually beneficial symbiosis, enhancing human health and maintaining gut microbial balance.
Bacteroides salanitronis levels are assessed in stool samples. Stool samples may be collected from the comfort of home.
Testing may require avoidance of certain medications and/or supplements including probiotics prior to sample collection. It is important to consult with the ordering provider for full test preparation instructions.
It is important to consult with the laboratory company used for test interpretation. Bacteroides levels are typically assessed by species, although some lesser-known species, such as Bacteroides salanitronis, may be reported as part of Bacteroides spp.
One lab company provides the following reference range for Bacteroides spp. levels alongside Prevotella spp., and reports this on a scale from -3 (low prevalence of these organisms) to +3 (high prevalence of these organisms). [16.]
High levels of Bacteroides in the gut microbiome are generally associated with a healthy state and favorable metabolic outcomes.
A high relative abundance of Bacteroides compared to other phyla like Firmicutes is considered essential for maintaining gut health, biodiversity, and homeostasis of metabolism, immune function, and colonization resistance.
Bacteroidetes, the phylum of which Bacteroides are a part, are considered a "keystone taxon" in the gut microbiome, and their depletion can lead to detrimental shifts in the microbial community structure. [12., 21.]
Several studies have found an association between high Bacteroidetes levels and a lean phenotype or healthy weight. A higher Bacteroidetes/Firmicutes ratio was associated with a lower body mass index (BMI). [8., 11.]
Conversely, a lower abundance of Bacteroidetes has been observed in obese individuals compared to lean individuals. [8.]
High levels of Bacteroidetes species like Bacteroides fragilis and B. thetaiotaomicron are considered beneficial as commensals, fermenting polysaccharides to produce short-chain fatty acids that serve as an energy source for the host. [21.]
They also contribute to bile acid metabolism and provide colonization resistance against pathogens like Clostridioides difficile. [21.]
However, elevated levels of Bacteroides in the setting of digestive symptoms or pathology warrants further assessment for bacterial strains such as enterotoxin-producing B. fragilis or B. caccae, which have been associated with digestive pathology in certain settings.
Lower levels of Bacteroides have been associated with inflammatory bowel diseases (IBD) like ulcerative colitis, where specific Bacteroides species exhibit significantly lower abundance compared to healthy controls.
The loss of these species is suggested to result from disease exacerbation and may serve as potential biomarkers for disease activity.
Low Bacteroides levels may disrupt microbial community dynamics, favoring the overgrowth of potentially harmful bacteria and diminishing the beneficial effects of Bacteroides-mediated functions, such as the fermentation of dietary fibers and production of short-chain fatty acids (SCFAs). [4.]
Therefore, maintaining a relatively high abundance of Bacteroides in the gut microbiome is generally considered a favorable state, associated with better metabolic health, a lean phenotype, and a lower risk of inflammatory conditions like IBD.
Monitoring Bacteroides levels may have clinical significance in assessing gut health, disease risk, and potential therapeutic interventions aimed at restoring a balanced microbiome.
A healthy diet and lifestyle are foundational for microbiome health.
While Bacteroides salanitronis is a valuable biomarker on its own, its diagnostic and prognostic utility can be significantly enhanced when used alongside other biomarkers.
The Firmicutes/Bacteroidetes ratio is an important marker of gut microbiota composition and health.
Bacteroides salanitronis belongs to the Bacteroidetes phylum, and changes in its levels can affect this ratio. A higher Firmicutes/Bacteroidetes ratio has been associated with obesity and metabolic disorders, while a lower ratio is often seen in individuals with inflammatory bowel disease (IBD).
By assessing the Firmicutes/Bacteroidetes ratio, clinicians can gain a more comprehensive understanding of the gut microbiome's state and its potential impact on health.
This integrated approach can help in diagnosing metabolic and inflammatory conditions and tailoring interventions to restore microbial balance.
Short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate, are products of microbial fermentation of dietary fibers in the gut. Bacteroides salanitronis and other Bacteroides species play a key role in the production of SCFAs through the degradation of polysaccharides.
Measuring SCFA levels in conjunction with Bacteroides salanitronis provides insights into the functional activity of the gut microbiome and its impact on host health.
SCFAs have anti-inflammatory properties and contribute to gut barrier integrity and energy metabolism. Alterations in SCFA levels can indicate dysbiosis and have been linked to conditions such as IBD, IBS, and metabolic syndrome.
By integrating SCFA measurements with Bacteroides salanitronis levels, clinicians can better assess gut health and develop targeted nutritional or probiotic therapies.
Inflammatory markers, such as C-reactive protein (CRP) and interleukins (e.g., IL-6), are commonly used to assess systemic inflammation and immune responses.
Since the gut microbiome plays a critical role in modulating inflammation, measuring inflammatory markers alongside Bacteroides salanitronis levels can provide valuable information about the interaction between the gut microbiota and the immune system.
Bacteroides salanitronis is a bacterium that is part of the human gut microbiome. This FAQ section addresses common questions about Bacteroides salanitronis, its significance, and its impact on health.
Bacteroides salanitronis is a species of Gram-negative, anaerobic bacteria that belongs to the Bacteroides genus. These bacteria are commonly found in the human gastrointestinal tract and play an important role in the digestion of complex carbohydrates and the maintenance of gut health.
In the gut microbiome, Bacteroides salanitronis helps break down and ferment complex carbohydrates that the human body cannot digest on its own.
This process produces short-chain fatty acids and other metabolites that are beneficial for gut health and overall metabolic functions.
Bacteroides salanitronis can be detected using microbiological and molecular techniques such as stool culture, 16S rRNA gene sequencing, and metagenomic analysis. These methods allow for the identification and quantification of Bacteroides salanitronis in the gut microbiome.
The benefits of Bacteroides salanitronis include aiding in the digestion of complex carbohydrates, producing beneficial short-chain fatty acids, supporting the gut barrier function, and helping maintain a balanced gut microbiome.
Under normal circumstances, Bacteroides salanitronis is beneficial and contributes to a healthy gut. However, an imbalance in the gut microbiome (dysbiosis) can sometimes lead to an overgrowth of Bacteroides species.
Bacteroides salanitronis interacts with other gut bacteria through competitive and cooperative relationships. These interactions help maintain a balanced gut microbiome, where beneficial bacteria support each other's growth and function while keeping pathogenic bacteria in check.
Supporting the growth of beneficial bacteria like Bacteroides salanitronis involves:
You should consult a healthcare provider if you experience persistent digestive issues such as abdominal pain, bloating, diarrhea, or constipation.
A healthcare provider can evaluate your symptoms, potentially recommend microbiome testing, and suggest appropriate treatments or dietary changes to improve gut health.
[1.] Bacteroidetes: The Jekyll and Hyde of the Human Gut Microbiome. Pharmacy Times. https://www.pharmacytimes.com/view/bacteroidetes-the-jekyll-and-hyde-of-the-human-gut-microbiome
[2.] Castaner O, Goday A, Park YM, Lee SH, Magkos F, Shiow STE, Schröder H. The Gut Microbiome Profile in Obesity: A Systematic Review. Int J Endocrinol. 2018 Mar 22;2018:4095789. doi: 10.1155/2018/4095789. PMID: 29849617; PMCID: PMC5933040.
[3.] Charles Robert Lichtenstern, Lamichhane-Khadka R. A tale of two bacteria – Bacteroides fragilis, Escherichia coli, and colorectal cancer. 2023;2. doi:https://doi.org/10.3389/fbrio.2023.1229077
[4.] Cronin P, Joyce SA, O'Toole PW, O'Connor EM. Dietary Fibre Modulates the Gut Microbiota. Nutrients. 2021 May 13;13(5):1655. doi: 10.3390/nu13051655. PMID: 34068353; PMCID: PMC8153313.
[5.] Elsaghir H, Reddivari AKR. Bacteroides Fragilis. [Updated 2023 May 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553032/
[6.] Gronow S, Held B, Lucas S, Lapidus A, Del Rio TG, Nolan M, Tice H, Deshpande S, Cheng JF, Pitluck S, Liolios K, Pagani I, Ivanova N, Mavromatis K, Pati A, Tapia R, Han C, Goodwin L, Chen A, Palaniappan K, Land M, Hauser L, Chang YJ, Jeffries CD, Brambilla EM, Rohde M, Göker M, Detter JC, Woyke T, Bristow J, Markowitz V, Hugenholtz P, Kyrpides NC, Klenk HP, Eisen JA. Complete genome sequence of Bacteroides salanitronis type strain (BL78). Stand Genomic Sci. 2011 Apr 29;4(2):191-9. doi: 10.4056/sigs.1704212. PMID: 21677856; PMCID: PMC3111984.
[7.] Hou, K., Wu, ZX., Chen, XY. et al. Microbiota in health and diseases. Sig Transduct Target Ther 7, 135 (2022). https://doi.org/10.1038/s41392-022-00974-4
[8.] Johnson EL, Heaver SL, Walters WA, Ley RE. Microbiome and metabolic disease: revisiting the bacterial phylum Bacteroidetes. J Mol Med (Berl). 2017 Jan;95(1):1-8. doi: 10.1007/s00109-016-1492-2. Epub 2016 Nov 29. PMID: 27900395; PMCID: PMC5187364.
[9.] JOHNSON JL, AULT DA. Taxonomy of the Bacteroides: II. Correlation of Phenotypic Characteristics with Deoxyribonucleic Acid Homology Groupings for Bacteroides fragilis and Other Saccharolytic Bacteroides Species. International Journal of Systematic Bacteriology. 1978;28(2):257-268. doi:https://doi.org/10.1099/00207713-28-2-257
[10.] Lan PTN, Sakamoto M, Sakata S, Benno Y. Bacteroides barnesiae sp. nov., Bacteroides salanitronis sp. nov. and Bacteroides gallinarum sp. nov., isolated from chicken caecum. International Journal of Systematic and Evolutionary Microbiology. 2006;56(12):2853-2859. doi:https://doi.org/10.1099/ijs.0.64517-0
[11.] Nishijima S, Suda W, Oshima K, Kim SW, Hirose Y, Morita H, Hattori M. The gut microbiome of healthy Japanese and its microbial and functional uniqueness. DNA Res. 2016 Apr;23(2):125-33. doi: 10.1093/dnares/dsw002. Epub 2016 Mar 6. PMID: 26951067; PMCID: PMC4833420.
[12.] Nomura K, Ishikawa D, Okahara K, Ito S, Haga K, Takahashi M, Arakawa A, Shibuya T, Osada T, Kuwahara-Arai K, Kirikae T, Nagahara A. Bacteroidetes Species Are Correlated with Disease Activity in Ulcerative Colitis. J Clin Med. 2021 Apr 17;10(8):1749. doi: 10.3390/jcm10081749. PMID: 33920646; PMCID: PMC8073534.
[13.] Ochoa-Repáraz J, Ramelow CC, Kasper LH. A Gut Feeling: The Importance of the Intestinal Microbiota in Psychiatric Disorders. Frontiers in Immunology. 2020;11. doi:https://doi.org/10.3389/fimmu.2020.510113
[14.] Pant A, Das B. Microbiome-based therapeutics: Opportunity and challenges. Progress in molecular biology and translational science. Published online January 1, 2022:229-262. doi:https://doi.org/10.1016/bs.pmbts.2022.07.006
[15.] Rios-Covian D, Salazar N, Gueimonde M, de Los Reyes-Gavilan CG. Shaping the Metabolism of Intestinal Bacteroides Population through Diet to Improve Human Health. Front Microbiol. 2017 Mar 7;8:376. doi: 10.3389/fmicb.2017.00376. PMID: 28326076; PMCID: PMC5339271.
[16.] Rupa Health. GI360 Microbiome Sample Report.pdf. Google Docs. https://drive.google.com/file/d/1hxpopw13KhiKJyZ9XnKPkfJBb8_4zP23/view
[17.] Salyers AA, Vercellotti JR, West SE, Wilkins TD. Fermentation of mucin and plant polysaccharides by strains of Bacteroides from the human colon. Appl Environ Microbiol. 1977 Feb;33(2):319-22. doi: 10.1128/aem.33.2.319-322.1977. PMID: 848954; PMCID: PMC170684.
[18.] Sato M, Kajikawa K, Kumon T, Watanabe D, Takase R, Hashimoto W. Mutually Beneficial Symbiosis Between Human and Gut-Dominant Bacteroides Species Through Bacterial Assimilation of Host Mucosubstances. Published online August 22, 2020. doi:https://doi.org/10.1101/2020.08.21.262261
[19.] Shin JH, Tillotson G, MacKenzie TN, Warren CA, Wexler HM, Goldstein EJC. Bacteroides and related species: The keystone taxa of the human gut microbiota. Anaerobe. 2024 Feb;85:102819. doi: 10.1016/j.anaerobe.2024.102819. Epub 2024 Jan 10. PMID: 38215933.
[20.] Wei, X., Yan, X., Zou, D. et al. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach. BMC Gastroenterol 13, 175 (2013). https://doi.org/10.1186/1471-230X-13-175
[21.] Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev. 2007 Oct;20(4):593-621. doi: 10.1128/CMR.00008-07. PMID: 17934076; PMCID: PMC2176045.
[22.] Wick EC, Sears CL. Bacteroides spp. and diarrhea. Curr Opin Infect Dis. 2010 Oct;23(5):470-4. doi: 10.1097/QCO.0b013e32833da1eb. PMID: 20697287; PMCID: PMC3079340.
[23.] Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011 Oct 7;334(6052):105-8. doi: 10.1126/science.1208344. Epub 2011 Sep 1. PMID: 21885731; PMCID: PMC3368382.
[24.] Xu J, Gordon JI. Honor thy symbionts. Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10452-9. doi: 10.1073/pnas.1734063100. Epub 2003 Aug 15. PMID: 12923294; PMCID: PMC193582.
[25.] Zafar H, Saier MH Jr. Gut Bacteroides species in health and disease. Gut Microbes. 2021 Jan-Dec;13(1):1-20. doi: 10.1080/19490976.2020.1848158. PMID: 33535896; PMCID: PMC7872030.
[26.] Zheng S, Zhou L, Hoene M, Peter A, Birkenfeld AL, Weigert C, Liu X, Zhao X, Xu G, Lehmann R. A New Biomarker Profiling Strategy for Gut Microbiome Research: Valid Association of Metabolites to Metabolism of Microbiota Detected by Non-Targeted Metabolomics in Human Urine. Metabolites. 2023 Oct 9;13(10):1061. doi: 10.3390/metabo13101061. PMID: 37887386; PMCID: PMC10608496.
[27.] Zhang J, Zhou J, He Z, Li H. Bacteroides and NAFLD: pathophysiology and therapy. Front Microbiol. 2024 Mar 20;15:1288856. doi: 10.3389/fmicb.2024.1288856. PMID: 38572244; PMCID: PMC10988783.
[28.] Coyne, M.J., Roelofs, K.G. & Comstock, L.E. Type VI secretion systems of human gut Bacteroidales segregate into three genetic architectures, two of which are contained on mobile genetic elements. BMC Genomics 17, 58 (2016). https://doi.org/10.1186/s12864-016-2377-z
[29.] Thomas F, Hehemann JH, Rebuffet E, Czjzek M, Michel G. Environmental and gut bacteroidetes: the food connection. Front Microbiol. 2011 May 30;2:93. doi: 10.3389/fmicb.2011.00093. PMID: 21747801; PMCID: PMC3129010.